# Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

> **NCT04003792** · PHASE2 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 49 (estimated)

## Conditions studied

- Liver Metastasis Colon Cancer

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** FOLFIRI Protocol
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04003792
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003792, "Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04003792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*